Evidence map›Paper›PMID 39752312›Full record

ArticleThe New England journal of medicine2025

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. Reply.

Alex F Herrera, Michael LeBlanc, Jonathan W Friedberg

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Alex F HerreraCity of Hope, Duarte, CA.
Michael LeBlancSWOG Statistics and Data Management Center, Seattle, WA.
Jonathan W FriedbergUniversity of Rochester, Rochester, NY jonathan_friedberg@urmc.rochester.edu.

Funding

SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MEGAN OTHUS · 2014 to 2026
$115.2M
Leading NCI Clinical Trials Network research nationally and at the City of Hope Comprehensive Cancer CenterR50CA285409 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Alex F. Herrera · 2024 to 2026
$624k
NCI NIH HHS R50 CA285409NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180888
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39752312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.